 Disease-modifying agents experimental treatments rheumatoid arthritis pharmacologic management rheumatoid arthritis RA patient use various classes therapeutic agents symptomatic relief disease activity Aspirin nonsteroidal antiinflammatory drugs degree pain inflammatory disease process addition heterogeneous class compounds second-line therapy disease-modifying antiinflammatory rheumatic drugs disease course Second-line treatments antimalarials gold salts D-penicillamine azathioprine methotrexate placebo-controlled trials efficacy compounds RA Improvement standard parameters disease activity number painful swollen joints duration morning stiffness erythrocyte sedimentation rate second-line drugs roentgenographic progression rigorous study agents combination complete disease remission therapies intensive investigation sulfasalazine combination therapy